Atypical Pyoderma Gangrenosum with Ulcerative Colitis treated successfully with prednisolone and mesalazine: A case report

Main Article Content

Doaa AE Abou-Taleb*
Mahmoud F Sherif
Ahmed S Mohammed

Abstract

Introduction: Pyoderma Gangrenosum (PG) manifests as recurrent deep ulceration of the skin and PG is often associated with a variety of systemic diseases, such as Inflammatory Bowel Diseases (IBD), inflammatory arthropathies, hematologic malignancies and hepatitis. There has been neither laboratory finding nor histological feature diagnostic of PG, and diagnosis of PG is mainly made based on the exclusion criteria.


Patient and methods: A male patient 21 years old, complained of rectal bleeding of 3 weeks duration. He presented with a large, painful and rapidly progressive cutaneous ulcer in the right flank. Laboratory and microbiological investigations, colonoscopic biopsy and a skin biopsy from the ulcer were performed.


Results: An atypical presentation of PG with Ulcerative Colitis (UC) was diagnosed. The PG rapidly resolved after starting treatment with prednisolone and mesalazine and the ulcer healed with scar. After successful treatment the patient suddenly stopped all his treatment and he came back again with rectal bleeding and a rounded, painful and rapidly progressive cutaneous ulcer in each cheek. One month after starting prednisolone and mesalazine treatment, complete healing of both ulcers has occurred.


Conclusion: A rare atypical presentation of PG with risk of misdiagnosis and the rapid healing of PG with combination of prednisolone and mesalazine therapy were concluded.

Downloads

Download data is not yet available.

Article Details

Abou-Taleb, D. A., Sherif, M. F., & Mohammed, A. S. (2021). Atypical Pyoderma Gangrenosum with Ulcerative Colitis treated successfully with prednisolone and mesalazine: A case report. Global Journal of Medical and Clinical Case Reports, 8(2), 065–068. https://doi.org/10.17352/2455-5282.000131
Case Reports

Copyright (c) 2021 Abou-Taleb DAE, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Vacas AS, Torre AC, Bollea-Garlatti ML, Warley F, Galimberti RL (2017) Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients. Int J Dermatol 56: 386-391. Link: https://bit.ly/3eGNbI5

Pereira N, Brites MM, Goncalo M, Tellechea O, Figueiredo A (2013) Pyoderma gangrenosum - a review of 24 cases observed over 10 years. Int J Dermatol 52: 938-945. Link: https://bit.ly/3eBme8v

Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, et al. (2013) Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol 45: 202-210. Link: https://bit.ly/3iu99Pz

Yasin F, Assad S, Zahid M, Malik SA (2017) Extensive pyoderma gangrenosum: a challenging diagnosis and literature review of management. Cureus 9: e1486. Link: https://bit.ly/36NaMCr

Marzano AV, Borghi A, Wallach D, Cugno M (2018) A comprehensive review of neutrophilic diseases. Clin Rev Allergy Immunol 54: 114-130. Link: https://bit.ly/3iu9dih

Ahn C, Negus D, Huang W (2018) Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol 14: 225-233. Link: https://bit.ly/36RR8oU

Brunsting LA, Underwood LJ (1949) Pyoderma vegetans in association with chronic ulcerative colitis. Arch Derm Syphilol 60: 161-172. Link: https://bit.ly/3kFyQzy

Ahronowitz I, Harp J, Shinkai K (2012) Etiology and management of pyoderma gangrenosum. Am J Clin Dermatol 13: 191-211. Link: https://bit.ly/3hT4CXV

TripodiCutrì F, Salerno R, Lo Schiavo A, Gravina AG, Romano M, et al. (2009) Ulcerative colitis associated with leukocytoclastic vasculitis of the skin. Dig Liver Dis 41: e42- e44. Link: https://bit.ly/3hVi7GK

Nishiwaki T, Ina K, Goto H, Watanabe O, Tsuzuki T, et al. (2005) Possible involvement of the interleukin-15 and interleukin-15 receptor system in a heightened state of lamina propria B cell activation and differentiation in patients with inflammatory bowel disease. J Gastroenteral 40:128-136. Link: https://bit.ly/3xWCFnA

Oka M (2007) Pyoderma gangrenosum and interleukin 8. Br J Dermatol 157: 1279-1281. Link: https://bit.ly/3zlZDoK

Ashchyan HJ, Butler DC, Nelson CA, Noe MH, Tsiaras WG, et al. (2018) The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA Dermatol 154: 409-413. Link: https://bit.ly/3eBXT2I

Alavi A, French LE, Davis MD, Brassard A, Kirsner RS (2017) Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol 18: 355-372. Link: https://bit.ly/3BzPTcm

Futami H, KodairaM, Furuta T, Hanai H, Kaneko E (1998) Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and cyclosporine. J Gastroenteral 33: 408-411. Link: https://bit.ly/3rskzYq

Reichrath J, Bens G, Bonowitz A, Tilgen W (2005) Treatment recommendations for pyoderma gangrenosum: an evidence based review of the literature based on more than 350 patients. J Am Acad Dermatol 53: 273-283. Link: https://bit.ly/3eEvedo

Sandborn WJ (2008) Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations? J Clin Gastroenterol 42: 338-344. Link: https://bit.ly/3hTeqkP

Lee JI, Park HJ, Lee JY, Cho BK (2010) A Case of Pyoderma Gangrenosum with Ulcerative Colitis Treated with Mesalazine. Ann Dermatol 22: 422-425. Link: https://bit.ly/36QJLy4

Sanders CJ, Hulsmans RF (1993) Successful treatment of pyoderma gangrenosum with topical 5-aminosalicylic acid. Cutis 51: 262-264. Link: https://bit.ly/2W5cJIz